/CYPH

CYPH Stock - Cypherpunk Technologies Inc.

Q: What is the analyst price target for CYPH?

Analyst price target information is not currently available for CYPH.

Q: What is CYPH's market cap?

Market capitalization information is not currently available for CYPH.

Healthcare|Biotechnology|NASDAQ

$1.30+39.02%

+$0.36 (+39.02%) • Dec 19

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

BUY

High Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

100

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

100

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

100

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+323.1%upside

Target: $5.50

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for CYPH

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2020

FY2021

FY2022

FY2023

FY2024

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta-0.14

52W High$3.70

52W Low$0.22

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2024	FY2023	FY2022	FY2021	FY2020
Revenue	N/A	N/A	N/A	$1.50M	$10.05M
Gross Profit	N/A	$-427,000	N/A	$1.50M	$5.12M
Gross Margin	N/A	N/A	N/A	100.0%	50.9%
Operating Income	$-70,057,000	$-87,041,000	$-56,763,000	$-41,426,000	$-3,446,000
Net Income	$-67,555,000	$-81,414,000	$-54,596,000	$-40,587,000	$-3,387,000
Net Margin	N/A	N/A	N/A	-2705.8%	-33.7%
EPS	$-1.81	$-3.98	$-4.82	$-4.73	$-4.64

Company Overview

Cypherpunk Technologies Inc., a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead clinical stage drug candidate includes DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in various ongoing clinical trials for treating esophagogastric and gynecologic cancers, and colorectal cancer. The company also develops FL-501, a monoclonal antibody that inhibits GDF-15 protein that is in preclinical trial. It has an option and license agreement with Adimab, LLC and BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as Leap Therapeutics, Inc. and changed its name to Cypherpunk Technologies Inc. in November 2025. The company was incorporated in 2011 and is based in Cambridge, Massachusetts.

Visit Website

Earnings History & Surprises

CYPH

Beat Rate

53%

Last 19 quarters

Avg Surprise

-15.8%

EPS vs Estimate

Beats / Misses

10/9

Last 12 quarters

Latest EPS

$-0.08

Q4 2025

EPS Surprise History

Q1 24

+17.9%

$-0.46vs$-0.56

Q2 24

+10.5%

$-0.51vs$-0.57

Q3 24

-23.8%

$-0.52vs$-0.42

Q4 24

+4.3%

$-0.44vs$-0.46

Q1 25

+5.1%

$-0.37vs$-0.39

Q2 25

+2.6%

$-0.37vs$-0.38

Q3 25

-37.9%

$-0.40vs$-0.29

Q4 25

+66.7%

$-0.08vs$-0.24

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q1 2026	Mar 25, 2026	—	—	—	—
Q4 2025	Nov 12, 2025	$-0.24	$-0.08	+66.7%	✓ BEAT
Q3 2025	Aug 14, 2025	$-0.29	$-0.40	-37.9%	✗ MISS
Q2 2025	May 13, 2025	$-0.38	$-0.37	+2.6%	✓ BEAT
Q1 2025	Mar 26, 2025	$-0.39	$-0.37	+5.1%	✓ BEAT
Q4 2024	Nov 13, 2024	$-0.46	$-0.44	+4.3%	✓ BEAT
Q3 2024	Aug 12, 2024	$-0.42	$-0.52	-23.8%	✗ MISS
Q2 2024	May 13, 2024	$-0.57	$-0.51	+10.5%	✓ BEAT
Q1 2024	Mar 18, 2024	$-0.56	$-0.46	+17.9%	✓ BEAT
Q4 2023	Nov 13, 2023	$-0.48	$-0.51	-6.3%	✗ MISS
Q3 2023	Aug 14, 2023	$-0.98	$-0.91	+7.1%	✓ BEAT
Q2 2023	May 15, 2023	$-0.90	$-3.20	-255.6%	✗ MISS
Q1 2023	Mar 24, 2023	$-0.90	$-1.10	-22.2%	✗ MISS
Q4 2022	Nov 14, 2022	$-1.10	$-1.30	-18.2%	✗ MISS
Q3 2022	Aug 12, 2022	$-1.00	$-1.50	-50.0%	✗ MISS
Q2 2022	May 13, 2022	$-1.10	$-0.90	+18.2%	✓ BEAT
Q1 2022	Mar 11, 2022	$-1.10	$-1.00	+9.1%	✓ BEAT
Q4 2021	Nov 12, 2021	$-1.10	$-1.40	-27.3%	✗ MISS
Q3 2021	Aug 13, 2021	$-1.30	$-1.20	+7.7%	✓ BEAT
Q2 2021	May 14, 2021	$-1.10	$-1.20	-9.1%	✗ MISS

Frequently Asked Questions about CYPH

What is CYPH's current stock price?

Cypherpunk Technologies Inc. (CYPH) is currently trading at $1.30 per share. The stock has moved +39.02% today.

What is the analyst price target for CYPH?

The average analyst price target for CYPH is $5.50, based on 1 analyst.

What sector is Cypherpunk Technologies Inc. in?

Cypherpunk Technologies Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.

What is CYPH's market cap?

Cypherpunk Technologies Inc. has a market capitalization of $0.07 billion, making it a small-cap company.

Does CYPH pay dividends?

No, Cypherpunk Technologies Inc. does not currently pay a dividend to shareholders.